2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.Peer-Reviewed Original ResearchConceptsBreast cancerDose-escalation clinical trialHDAC6 inhibitor ricolinostatMetastatic breast cancerPan-HDAC inhibitorsHistone deacetylaseHuman breast cancerIndividual histone deacetylaseSensitive cancer cellsNab-paclitaxelClinical responseMetastatic BCPredictive biomarkersClinical trialsClinical activityPreclinical studiesTumor typesHDAC6 activityCancer cellsHDAC6iAnticancer strategyPatientsRicolinostatCancerMultiple cohortsPTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development
Grinman DY, Boras-Granic K, Takyar FM, Dann P, Hens JR, Marmol C, Lee J, Choi J, Chodosh LA, Sola MEG, Wysolmerski JJ. PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development. Breast Cancer Research 2022, 24: 30. PMID: 35440032, PMCID: PMC9020078, DOI: 10.1186/s13058-022-01523-1.Peer-Reviewed Original ResearchConceptsOverexpression of PTHrPSecretory differentiationEpithelial cellsPTHrP overexpressionTumor latencyBreast cancerMammary epithelial cellsType 1 PTH/PTHrP receptorMMTV-PyMT breast cancer modelPTH/PTHrP receptorMMTV-PyMT miceMammary tumor developmentBreast cancer riskBreast cancer biologyExpression of PTHrPHormone-related proteinHuman breast cancerBreast cancer modelE74-like factor 5Normal mammary epithelial cellsBreast cancer progressionMouse mammary tumorsExpression of markersAlveolar epithelial cellsLuminal epithelial cells
2020
Electronic cigarettes promotes the lung colonization of human breast cancer in NOD-SCID-Gamma mice.
Huynh D, Huang J, Le LTT, Liu D, Liu C, Pham K, Wang H. Electronic cigarettes promotes the lung colonization of human breast cancer in NOD-SCID-Gamma mice. International Journal Of Clinical And Experimental Pathology 2020, 13: 2075-2081. PMID: 32922603, PMCID: PMC7476960.Peer-Reviewed Original ResearchE-cigsNOD-SCIDGamma miceTumor cellsCig vapour extractElectronic cigarette smokingHuman breast cancer cell line MDA-MB-231Breast cancer cell line MDA-MB-231Cancer cell line MDA-MB-231Human breast cancer cellsCell line MDA-MB-231E-cig exposureHuman breast cancerMetastasis-promoting effectsTail vein injectionBreast cancer cellsTumor cell proliferationMDA-MB-231Tumor cell apoptosisCig exposureCigarette smokingLung metastasesTumor loadTumor mortalityBreast cancer
2019
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal S, Jacobs A, Windhager J, Silina K, van den Broek M, Dedes K, Martínez M, Weber W, Bodenmiller B. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell 2019, 177: 1330-1345.e18. PMID: 30982598, PMCID: PMC6526772, DOI: 10.1016/j.cell.2019.03.005.Peer-Reviewed Original ResearchConceptsBreast cancerBreast cancer ecosystemsTumor-associated macrophagesResponse to therapyHuman breast tumorsTumor cell compositionHuman breast cancerNon-tumor tissue samplesPrecision medicine approachT cellsBreast tumorsImmune cellsPoor prognosisAntibody panelTumor cellsTumor ecosystemHeterogeneous diseaseClinical dataDisease progressionTumorSingle-cell atlasMass cytometryPhenotypic abnormalitiesMedicine approachImmune ecosystem
2018
Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells
Jeong J, Choi J, Kim W, Dann P, Takyar F, Gefter JV, Friedman PA, Wysolmerski J. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells. Journal Of Biological Chemistry 2018, 294: 887-901. PMID: 30463939, PMCID: PMC6341383, DOI: 10.1074/jbc.ra118.004143.Peer-Reviewed Original ResearchConceptsBreast cancer cellsBreast cancerCancer cellsHER2-positive breast cancer cell linesHER2-positive breast cancer cellsInvasive breast cancerDegradation of HER2Breast cancer cell linesHuman breast cancerNormal mammary epithelial cellsInhibition of EzrinHER2 tyrosine kinaseErbB family membersPMCA2 levelsCancer cell linesDuctal carcinomaHER2 expressionHER2 levelsMammary epithelial cellsHER2Human patientsPharmacologic inhibitionActive HER2Ezrin expressionGenetic knockdown
2017
Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression
Aggarwal A, Feldman D, Feldman B. Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression. The Journal Of Steroid Biochemistry And Molecular Biology 2017, 177: 155-158. PMID: 28710021, PMCID: PMC5764828, DOI: 10.1016/j.jsbmb.2017.07.003.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyBreast cancerD deficiencyPoor outcomeInhibit breast cancer growthAssociated with worse prognosisLow vitamin D levelsAggressive molecular phenotypePrimary tumor growthSerum 25(OH)D concentrationsDevelopment of metastasesVitamin D levelsBreast cancer growthBreast cancer patientsHuman breast cancerVitamin D signalingVitamin D receptorBreast cancer cellsVitamin D actionPrimary tumorWorse prognosisD levelsTumor progressionTumor growthD receptorCharacterization of potential driver mutations involved in human breast cancer by computational approaches
Rajendran B, Deng C. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget 2017, 5: 50252-50272. PMID: 28477017, PMCID: PMC5564847, DOI: 10.18632/oncotarget.17225.Peer-Reviewed Original ResearchConceptsBreast cancerHuman breast cancerBreast cancer initiationForms of cancerPotential driver mutationsLethal cancersBreast tumorigenesisCancerDriver mutationsTumor initiationGenetic mutationsCancer initiationDriver genesPathway analysisProgressionMutation genesCellular regulatory pathwaysCandidate driversRegulatory pathwaysMetastasisCancer driversInitiationHER2 signaling regulates HER2 localization and membrane retention
Jeong J, Kim W, Kim LK, VanHouten J, Wysolmerski JJ. HER2 signaling regulates HER2 localization and membrane retention. PLOS ONE 2017, 12: e0174849. PMID: 28369073, PMCID: PMC5378417, DOI: 10.1371/journal.pone.0174849.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsApoptosisBreast NeoplasmsCalciumCell Line, TumorCell MembraneCell ProliferationErbB ReceptorsGene Knockdown TechniquesHumansIntracellular SpaceLapatinibPlasma Membrane Calcium-Transporting ATPasesQuinazolinesReceptor, ErbB-2Receptor, ErbB-3RNA, Small InterferingUbiquitinationConceptsMembrane protrusionsCell surfaceSpecific plasma membrane domainsPlasma membrane domainsReceptor tyrosine kinasesMembrane domainsErbB family membersErbB3/HER3Tyrosine kinaseGenetic knockdownHER2 ubiquitinationHER2/HER3PMCA2 expressionPharmacologic inhibitionUbiquitinationERBB2 geneHsp90HER2/EGFRCalcium pumpMembrane retentionInternalizationHuman breast cancerFamily membersHER3Expression
2016
Bisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine Dysregulation in the Mouse Mammary Gland: A Potential Mechanism Programming Breast Cancer Risk
Fischer C, Mamillapalli R, Goetz T, Jorgenson E, Ilagan Y, Taylor HS. Bisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine Dysregulation in the Mouse Mammary Gland: A Potential Mechanism Programming Breast Cancer Risk. Discover Oncology 2016, 7: 241-251. PMID: 26911702, PMCID: PMC10726733, DOI: 10.1007/s12672-016-0254-5.Peer-Reviewed Original ResearchConceptsBPA exposureBreast cancerAdaptive immunityMammary glandPosterior mammary glandsTh1 T cellsAberrant immune responseAbnormal mammary gland developmentHuman breast cancerPossible environmental etiologyInterleukin-1 gene familyMammary gland developmentMouse mammary tissueCytolytic CD8Osmotic minipumpsCD1 miceT cellsImmune responseGene familyExpression of membersCXC familyMammary tissueDevelopmental programmingUteroWestern blot
2015
PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ. PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 2015, 35: 2961-2970. PMID: 26640141, PMCID: PMC4896860, DOI: 10.1038/onc.2015.377.Peer-Reviewed Original ResearchConceptsBreast cancerPIK3CA mutationsMammary tumorsHER2 amplification/overexpressionHER2-positive breast cancerHER2-positive cancersPrimary mammary tumorsHER2/HER3PIK3CA-activating mutationsHER2/neuHuman breast cancerEffective treatment approachAmplification/overexpressionCompound mouse modelMEK-ERK signalingMouse mammary glandWorse prognosisCombination therapyMammary tumorigenesisMouse modelMutant PIK3CATreatment approachesHER2Combined inhibitionCompensatory activation
2014
Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta).
Beck AP, Brooks A, Zeiss CJ. Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta). Journal Of The American Association For Laboratory Animal Science 2014, 64: 314-22. PMID: 25296018, PMCID: PMC4170097.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaBreast cancerDuctal carcinomaRhesus macaquesLifetime incidenceHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Nonhuman primatesGrowth factor receptor 2Extensive immunohistochemical analysisHuman breast cancerFactor receptor 2Human breast tumorsCell proliferation markersCommon malignancyPatient survivalPrognostic valueDuctular carcinomasPrognostication markersPrognostic markerBreast carcinomaMammary carcinomaMammary neoplasmsImmunohistochemical markersExtent of spread
2013
Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging.
Caragacianu D, Liu X, Norton I, Ide J, Richardson A, Dillon D, Jolesz F, Golshan M, Agar N. Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging. Journal Of Clinical Oncology 2013, 31: 1132-1132. DOI: 10.1200/jco.2013.31.15_suppl.1132.Peer-Reviewed Original ResearchBreast conserving surgeryAdjacent normal tissuesBreast cancerNormal tissuesCancer tissuesResidual cancer tissueInvasive breast cancer samplesSuccess of surgeryHuman breast cancerNormal breast tissueBreast cancer samplesConserving surgeryLumpectomy bedFatty acidsHuman tissue sectionsLipid profileHistopathology evaluationOperative procedureCancerous human tissuesAnatomical sitesTumor edgeCancer specimenArachidonic acidBreast tissueCancer
2012
Favorable outcome associated with an IGF-1 ligand signature in breast cancer
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Research And Treatment 2012, 133: 321-331. PMID: 22297468, DOI: 10.1007/s10549-012-1952-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesDisease-Free SurvivalFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IKaplan-Meier EstimateLigandsMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPrognosisReceptor, IGF Type 1Young AdultConceptsIGF-1 ligandBreast cancerFavorable outcomeInsulin-like growth factor (IGF) axisActivation signaturePrimary breast cancerGrowth factor axisPredictors of responseHuman breast cancerPathway analysisUpregulation of pathwaysBetter prognosisIGF axisPrognostic valueReceptor levelsLevels of mRNAFactor axisIGF ligandsIngenuity softwarePathway activation scoresCancerLigand levelsActivation scoresHigh groupProliferation pathways
2011
Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI
Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen Y, Hsu H, Fisher C, Tokayasu T, Olshen A, Spellman P, Gray J, Hylton N, Park C. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integrative Biology 2011, 3: 490-496. PMID: 21416100, PMCID: PMC3698966, DOI: 10.1039/c0ib00089b.Peer-Reviewed Original ResearchConceptsCancer-associated stromaMagnetic resonance imagingBreast magnetic resonance imagingBreast cancer patientsCancer patientsPrimary tumorBreast cancerBreast tissueInvasive breast cancerNormal-appearing breast tissueHuman breast cancerNormal breast tissueNon-invasive imaging techniqueLocal therapyBreast stromaMicrovessel densityIntact stromaBreast fibroglandular tissueCorrelative histologyTumor edgeResonance imagingLocal tissueArray comparative genomic hybridizationStromaCancer
2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 10208-10213. PMID: 20479250, PMCID: PMC2890442, DOI: 10.1073/pnas.0907011107.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Agents, HormonalBase SequenceBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesDNA PrimersFemaleGene Expression ProfilingHumansMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesMutationNeoplasms, Hormone-DependentOligonucleotide Array Sequence AnalysisPhosphatidylinositol 3-KinasesPrognosisProteinsProto-Oncogene Proteins c-aktReceptor, ErbB-2Receptors, EstrogenSignal TransductionSirolimusTamoxifenTOR Serine-Threonine KinasesTranscription FactorsConceptsBreast cancerPIK3CA mutationsClinical outcomesEstrogen receptor-positive breast cancerReceptor-positive breast cancerGene signaturePIK3CA mutation statusPI3K/mTOR inhibitorBetter clinical outcomesPI3K/mTOR inhibitionHuman breast cancerBC cell linesPIK3CA mutant breast cancersCommon genetic aberrationsTamoxifen monotherapyBetter prognosisMTOR inhibitorsBetter outcomesMutation statusMTOR inhibitionPathway activationExperimental modelGenetic aberrationsPrognosisCell lines
2009
Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Research And Treatment 2009, 123: 747-755. PMID: 20024612, DOI: 10.1007/s10549-009-0677-6.Peer-Reviewed Original ResearchMeSH KeywordsAlanineAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationComparative Genomic HybridizationDose-Response Relationship, DrugFemaleFibroblast Growth Factor 2Gene AmplificationGene DosageGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInhibitory Concentration 50Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphorylationProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 1RNA, MessengerSignal TransductionTriazinesConceptsFibroblast growth factor receptor 1Growth factor receptor 1Breast cancer cell linesBreast cancerFactor receptor 1Cancer cell linesKinase activityProtein overexpressionReceptor 1Cell linesCopy numberDirect anti-proliferative effectsGene expression profilingHuman breast cancerTyrosine kinase activityAnti-angiogenic effectsMDA-MB-361Small molecule inhibitorsAnti-proliferative effectsGrowth inhibitionDNA copy numberProtein expression levelsBrivanib treatmentFGFR-1 mRNANormal copy numberMolecular Classification of Normal and Cancer Mammospheres.
Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.Peer-Reviewed Original ResearchCancer stem cellsPrimary tumorBreast cancerTumor cellsStem cellsAbsence of CD24Breast cancer specimensHuman breast cancerFine-needle aspirationNormal breast tissueExpression of CD44Tumor tissue samplesPutative stem cell markersCD44-positive cellsKey protein markersEx vivo cultureStem cell markersNovel drug targetsSpecific therapyTreatment successNeedle aspirationCancer specimensMyoepithelial markersBT-20Positive cells
2008
ErbB3 is required for ductal morphogenesis in the mouse mammary gland
Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research 2008, 10: r96. PMID: 19019207, PMCID: PMC2656891, DOI: 10.1186/bcr2198.Peer-Reviewed Original ResearchConceptsTerminal end budsMammary fat padEnd budsMammary budBreast cancerFat padDuctal outgrowthMammary glandHER2/neuHuman breast cancerSmooth muscle actinNormal mammary glandSections of glandsMammary ductal treeMouse mammary gland developmentMammary gland developmentErbB3 functionMouse mammary glandRole of ErbB3Lobuloalveolar developmentEpithelial areaErbB2/HER2/NeuPredictive valueMuscle actinTherapeutic resistanceDoes Increased Expression of the Plasma Membrane Calcium-ATPase Isoform 2 Confer Resistance to Apoptosis on Breast Cancer Cells?
VanHouten J. Does Increased Expression of the Plasma Membrane Calcium-ATPase Isoform 2 Confer Resistance to Apoptosis on Breast Cancer Cells? 2008 DOI: 10.21236/ada493700.Peer-Reviewed Original ResearchPlasma membrane calcium ATPase isoform 2Cytosolic calcium levelsBreast cancer cellsCalcium levelsBreast cancerCalcium transportCancer cellsEstrogen receptor negativityHuman breast cancer cell linesBreast cancer cell linesHuman breast cancerElevated cytosolic calcium levelsCancer cell linesReceptor negativityMouse mammary glandTumor gradeYear survivalCalcium clearanceCalcium influxMammary epithelial cellsTransgenic modelDrug resistanceEpithelial contentExpression correlatesMammary glandAn Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research 2008, 68: 6084-6091. PMID: 18676830, PMCID: PMC2680495, DOI: 10.1158/0008-5472.can-07-6854.Peer-Reviewed Original ResearchConceptsPIK3CA mutationsBreast cancerAKT1 mutationsPTEN lossPathway aberrationsHormone receptor-positive breast cancer patientsHormone receptor-positive breast cancerPTEN mutationsReceptor-positive breast cancer patientsHormone receptor-positive cancersPI3K pathway aberrationsCell linesReceptor-positive breast cancerAdjuvant tamoxifen therapyReceptor-positive cancersBreast cancer patientsDifferent breast cancer subtypesDownstream PI3K/AktBasal-like tumorsBreast cancer subtypesHuman breast cancerPI3K inhibitor LY294002PI3K/AktK inhibitor LY294002PI3K inhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply